I won't talk about K medicine!2022 Medical Insurance negotiations for the preliminary review of the directory were announced, and the soul bargaining is coming again

The preliminary review of the 2022 version of the national medical insurance negotiations is finally released. On the evening of September 6, the National Medical Insurance Administration issued a notice and announced that the national medical insurance catalog that had passed the preliminary form of the preliminary form was announced, involving a total of 344 varieties. The planned plan outside the directory is 199 new varieties.

Some of the familiar varieties of some industries have entered the preliminary list, such as Yao Ming Junuo's CAR-T product Ruki Olun Saitor injection, and Fu Hong Hanlin's "H Medicine" Srusley monoclonal anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-resistance Injecting solution, Kangfang Biological PD-1/CTLA-4 dual-anti-product Kadinilicab, Roche's HER2 target ADC drug Enmendozumab.

Each time in the past, Meroshong's K medicine, BMW Schimi-Gui Bao's O medicine, this time, did not appear on the preliminary list, and the PD-1 and PD-L1 products of Astraon and Roche did not come. Essence In other words, in the medical insurance market next year, domestic enterprises do not have to worry about foreign -funded products to grab business.

Some interesting varieties have also entered the preliminary list. Ru Yuekang Pharmaceutical's anti-ED drugs are sour and sour. The company claims that two crickets each time, 1-2 times a week, 12 weeks of pills, total treatment costs less than 2,400 yuan, medical insurance can bear it.

In addition, rare disease treatment drugs such as Gobei and Fabre disease have also entered the preliminary list of medical insurance negotiations.

PD-1 is still the focus. Can CAR-T be on the negotiating table?

In early July this year, the information filling in the medical insurance negotiations has begun. The Jianzhi Bureau was informed that the national medical insurance information was flattened for a total of 537 corporate declaration information, involving 490 drugs (general names), and finally 344 drug reviews, with a pass rate of 70%.

This year's pass rate is slightly improved compared to 2021. Last year, a total of 474 drug declarations entered the medical insurance directory negotiations, and 271 drugs passed the review, with a pass rate of 58%.

PD-1 is still the focus of the negotiation of this medical insurance directory.

Hengrui's "Irika", Jun Shi's "Takai", "Baizean" in Baiji Shenzhou, and Nobuna's "Daber Shu Jun entered the review list of this medical insurance negotiation, and participated in the variety in the directory to increase adaptation to adaptation Symptoms.

Since the medical insurance negotiations in 2021, the Jianxian Bureau sorted out and found that the two indications of "Tuoyi" esophageal squamous squamous carcinoma and nasopharyngeal cancer were approved for listing; disease. The gastric cancer indication of "Dabu Shu" was also approved for listing in June this year.

The industry generally believes that as the indications of a variety of PD-1 products increase, it is inevitable that the field of treatment will cross each other, and the market "inner roll" will be upgraded again. Fu Hong Hanlin's Srusley monoclonal and Corning Jerry's Envoli Mippitive also joined.

Among the domestic varieties, the PD-1 of Yuheng Pharmaceutical and Cornerstone Pharmaceuticals did not enter the preliminary trial, while the Kangfang Bio was not included in the PD-1, but the dual anti-Kadinilicabe came into negotiation.

The PD-1 market is not like the ideas at the time in the early days, so that companies are not able to raise interest. At the end of August, at the mid -term performance media communication meeting of Fuhong Hanlin in 2022, the company's chief business officer Yu Cheng told the media: Sruoli Mipide currently has only one indication, the price reduction of the product may not be great, the company's strategy may be It has not been determined.

In addition to PD-1, Rocky Olun, which had been highly hoped for and had a high hopes for each of the industry, passed the preliminary review of medical insurance negotiations. However, Fosun Kate's CAR-T product Aquelun Saitor injection did not enter the preliminary list.

In the first half of 2021, Yin Mingjuo's Rocky Lenza opened 77 prescriptions to complete the loss of 64 patients, and its operating income reached 66 million yuan. Obviously, entering the medical insurance directory is the only way out of CAR-T products, but it still depends on the price reduction of enterprises.

For drugs with more expensive prices, the State Medical Insurance Bureau clearly states that it always firmly grasps the functional positioning of basic medical insurance "insurance basic", and greatly reduces the price of exclusive drugs through admission negotiations.

Many rare diseases enter, and the annual treatment costs have dropped to less than 300,000?

Following PD-1 and CAR-T and other innovative drugs, Edala's key monitoring varieties such as injections, Malaysian cinnamon Zitt injections, Belling capsules and other key monitoring varieties, as well as lipid-reducing lipids that have been exited from local medical insurance Capsules and other varieties have attracted much attention from the industry through preliminary review.

The industry generally believes that companies in the above -mentioned varieties have re -applied for medical insurance negotiations again, which is obviously trying to extend the life of the product. However, whether you can enter the medical insurance directory in the end, you need to wait for the unified evaluation of the experts.

When the National Medical Insurance Bureau launched this year's price negotiation work, it is clearly tilted to special groups such as patients with rare diseases and children. The Jianzhi Bureau found that rare diseases did not set the time limit for "approval of listing after January 1, 2017", which undoubtedly coincided with the country's policy policy that encouraged rare disease diagnosis and treatment.

As a special effect of treating type Ⅰ Gecie's disease, after the injection ofinosidinase is used to enter some provinces, it has passed preliminary review of state talks this year. There are no more than 1,000 patients in Gogh's disease, and cases are mainly concentrated in Hebei, Shandong, Henan, and Liaoning. Agotase β was also entered into the preliminary list.

Not only rare medicine, Pfizer's injection of Ogayzumab, Villeci Mosaic Film in Bayer, Eneari Pearl Mipide of Hansen Pharmaceutical, and GSK's Meipilizumab, Albervi’s Eunmeter Mipidumab for the Injuki Metrack of Vena carats and Roche belongs to innovative drugs.

The Jianxian Bureau was informed that the medical insurance negotiations over the years have standards for selected drug prices. The annual treatment costs have been reduced to 500,000 yuan to enter the audit list. However, the real negotiation is successful. under.

In this year's declaration requirements, companies need to provide drug prices and actual sales in the first half of the year. However, this information has not been publicized, but the Medical Insurance Bureau discloses information such as the effectiveness, safety, economy, innovation and fairness of the application of drugs.

In the next step, according to the feedback received by the National Medical Insurance Bureau, the relevant information was further verified, and the scope of drugs that finally passed the formal review were determined and announced to the society. Subsequently, the National Medical Insurance Administration will promote follow -up work such as reviewing expert review and negotiation bidding.

In the end, which medicines will be adjusted into the transfer, the final result will be produced in November, and the Jianzhi Bureau will continue to pay attention.

Writing ｜ Xiaomi

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

Illustration ｜ Visual China

Attachment: 2022 medical insurance directory outside Western medicine and Chinese patent medicine list, 2022 medical insurance directory western medicine and Chinese patent medicine list

####

- END -